Literature DB >> 23856888

Mucins in pancreatic cancer and its microenvironment.

Sukhwinder Kaur1, Sushil Kumar, Navneet Momi, Aaron R Sasson, Surinder K Batra.   

Abstract

Pancreatic cancer remains a lethal malignancy with poor prognosis owing to therapeutic resistance, frequent recurrence and the absence of treatment strategies that specifically target the tumour and its supporting stroma. Deregulated cell-surface proteins drive neoplastic transformations and are envisioned to mediate crosstalk between the tumour and its microenvironment. Emerging studies have elaborated on the role of mucins in diverse biological functions, including enhanced tumorigenicity, invasiveness, metastasis and drug resistance through their characteristic O-linked and N-linked oligosaccharides (glycans), extended structures and unique domains. Multiple mucin domains differentially interact and regulate different components of the tumour microenvironment. This Review discusses: the expression pattern of various mucins in the pancreas under healthy, inflammatory, and cancerous conditions; the context-dependent attributes of mucins that differ under healthy and pathological conditions; the contribution of the tumour microenvironment in pancreatic cancer development and/or progression; diagnostic and/or prognostic efficacy of mucins; and mucin-based therapeutic strategies. Overall, this information should help to delineate the intricacies of pancreatic cancer by exploring the family of mucins, which, through various mechanisms in both tumour cells and the microenvironment, worsen disease outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23856888      PMCID: PMC3934431          DOI: 10.1038/nrgastro.2013.120

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  151 in total

Review 1.  From glycomics to functional glycomics of sugar chains: Identification of target proteins with functional changes using gene targeting mice and knock down cells of FUT8 as examples.

Authors:  Akihiro Kondo; Wenzhe Li; Takatoshi Nakagawa; Miyako Nakano; Nobuto Koyama; Xiangchun Wang; Jianguo Gu; Eiji Miyoshi; Naoyuki Taniguchi
Journal:  Biochim Biophys Acta       Date:  2006-11-10

2.  Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy.

Authors:  Koichiro Tsutsumi; Hirofumi Kawamoto; Ken Hirao; Ichiro Sakakihara; Naoki Yamamoto; Yasuhiro Noma; Masakuni Fujii; Hironari Kato; Tsuneyoshi Ogawa; Etsuji Ishida; Kenji Kuwaki; Kazuhiro Nouso; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  Pancreatology       Date:  2012-08-04       Impact factor: 3.996

3.  Biphasic effect of cell surface sialic acids on pancreatic cancer cell adhesiveness.

Authors:  T Sawada; J J Ho; T Sagabe; W H Yoon; Y S Chung; M Sowa; Y S Kim
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

4.  Expression of galectin-3 in pancreatic ductal adenocarcinoma.

Authors:  Matthias M Gaida; Sylvia T Bach; Frank Günther; Billur Baseras; Darjus F Tschaharganeh; Thilo Welsch; Klaus Felix; Frank Bergmann; Gertrud M Hänsch; Moritz N Wente
Journal:  Pathol Oncol Res       Date:  2011-09-12       Impact factor: 3.201

5.  Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.

Authors:  Michael S Turner; Patrice A Cohen; Olivera J Finn
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Ajay V Maker; Nora Katabi; Mithat Gonen; Ronald P DeMatteo; Michael I D'Angelica; Yuman Fong; William R Jarnagin; Murray F Brennan; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2010-08-18       Impact factor: 5.344

7.  Unfolding dynamics of the mucin SEA domain probed by force spectroscopy suggest that it acts as a cell-protective device.

Authors:  Thaher Pelaseyed; Michael Zäch; Asa C Petersson; Frida Svensson; Denny G A Johansson; Gunnar C Hansson
Journal:  FEBS J       Date:  2013-02-21       Impact factor: 5.542

8.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

Authors:  Ramesh K Ramanathan; Kenneth M Lee; John McKolanis; Elizabeth Hitbold; Wolfgang Schraut; Arthur J Moser; Elizabeth Warnick; Theresa Whiteside; Jennifer Osborne; Hyoung Kim; Roger Day; Monica Troetschel; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2004-09-14       Impact factor: 6.968

9.  Gel-forming mucins appeared early in metazoan evolution.

Authors:  Tiange Lang; Gunnar C Hansson; Tore Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

10.  Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages.

Authors:  P Allavena; M Chieppa; G Bianchi; G Solinas; M Fabbri; G Laskarin; A Mantovani
Journal:  Clin Dev Immunol       Date:  2011-02-09
View more
  116 in total

Review 1.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

2.  Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma.

Authors:  Michiyo Higashi; Seiya Yokoyama; Takafumi Yamamoto; Yuko Goto; Ikumi Kitazono; Tsubasa Hiraki; Hiroki Taguchi; Shinichi Hashimoto; Yoshihiko Fukukura; Chihaya Koriyama; Yuko Mataki; Kosei Maemura; Hiroyuki Shinchi; Maneesh Jain; Surinder K Batra; Suguru Yonezawa
Journal:  Pancreas       Date:  2015-07       Impact factor: 3.327

Review 3.  Fluorescent imaging of cancerous tissues for targeted surgery.

Authors:  Lihong Bu; Baozhong Shen; Zhen Cheng
Journal:  Adv Drug Deliv Rev       Date:  2014-07-24       Impact factor: 15.470

4.  Physical biology of the cancer cell glycocalyx.

Authors:  Joe Chin-Hun Kuo; Jay G Gandhi; Roseanna N Zia; Matthew J Paszek
Journal:  Nat Phys       Date:  2018-07-04       Impact factor: 20.034

Review 5.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

6.  Equilibrium Modeling of the Mechanics and Structure of the Cancer Glycocalyx.

Authors:  Jay G Gandhi; Donald L Koch; Matthew J Paszek
Journal:  Biophys J       Date:  2019-01-15       Impact factor: 4.033

7.  Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival.

Authors:  S Joshi; S Kumar; M P Ponnusamy; S K Batra
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

Review 8.  The tumour glyco-code as a novel immune checkpoint for immunotherapy.

Authors:  Ernesto RodrÍguez; Sjoerd T T Schetters; Yvette van Kooyk
Journal:  Nat Rev Immunol       Date:  2018-02-05       Impact factor: 53.106

Review 9.  Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Authors:  Catherine M Sielaff; Shaker A Mousa
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

10.  Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling.

Authors:  Ming Zhou; Zhenyu Ye; Yizhou Gu; Bian Tian; Bian Wu; Juncheng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.